Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (21,787)	$ (16,149)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,466	1,468
Noncash lease expense	210	322
Stock-based compensation expense	1,107	621
Change in fair value of stock warrants	(6,532)	(930)
Change in fair value of contingent consideration	4,200	417
Operating loss on minority interest investment		478
Change in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	122	154
Due from related party		55
Accounts payable	1,215	801
Accrued compensation	473	4
Accrued clinical trial site costs	1,400	711
Operating lease liabilities	(224)	(318)
Other liabilities	(7)	67
Net cash used in operating activities	(18,357)	(12,299)
Cash flows from investing activities:
Purchases of property and equipment	(3)	(16)
Security deposit on sublease		(59)
Proceeds from sale of minority interest investment in former subsidiary		500
Net cash provided by (used in) investing activities	(3)	425
Cash flows from financing activities:
Proceeds from sale of common stock, net of costs	53,760
Proceeds from stock option exercises	17
Principal paid on finance lease liabilities	(13)
Net cash provided by financing activities	53,764
Net increase (decrease) in cash and cash equivalents	35,404	(11,874)
Cash and cash equivalents, beginning of period	20,733	23,099
Cash and cash equivalents, end of period	56,137	11,225
Supplemental disclosure of non-cash investing and financing information
Purchases of property and equipment in accounts payable	3
Purchases of property and equipment with capital lease obligation		$ 28
Financing costs in accounts payable and accrued liabilities	$ 38